These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19768419)

  • 1. Considerations for licensure of influenza vaccines with pandemic and prepandemic indications.
    Baylor NW; Houn F
    Curr Top Microbiol Immunol; 2009; 333():453-70. PubMed ID: 19768419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].
    Loulergue P; Launay O
    Med Sci (Paris); 2009; 25(8-9):719-25. PubMed ID: 19765386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emulsion-based adjuvants for influenza vaccines.
    Vogel FR; Caillet C; Kusters IC; Haensler J
    Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1-3, 2010.
    Haaheim LR; Katz JM
    Influenza Other Respir Viruses; 2011 Jul; 5(4):288-95. PubMed ID: 21651740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress with human H5N1 vaccines: a perspective from industry.
    Palache B; Krause R
    Expert Rev Vaccines; 2009 Apr; 8(4):391-400. PubMed ID: 19348556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans.
    Jennings LC; Monto AS; Chan PK; Szucs TD; Nicholson KG
    Lancet Infect Dis; 2008 Oct; 8(10):650-8. PubMed ID: 18922487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
    J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.
    Leroux-Roels G
    Expert Opin Biol Ther; 2009 Aug; 9(8):1057-71. PubMed ID: 19555313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflunov(®): a prepandemic influenza vaccine.
    Gasparini R; Amicizia D; Lai PL; Panatto D
    Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines in development against avian influenza.
    Cox MM
    Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pandemic influenza vaccines. Concepts, European mock-up licenses, and acceptance criteria].
    Pfleiderer M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Dec; 53(12):1242-9. PubMed ID: 21161474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
    Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D
    Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.
    Abelin A; Colegate T; Gardner S; Hehme N; Palache A
    Vaccine; 2011 Feb; 29(6):1135-8. PubMed ID: 21115061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.
    Rudenko L; Isakova-Sivak I
    Expert Rev Vaccines; 2015 Mar; 14(3):395-412. PubMed ID: 25555687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pandemic influenza threat and preparedness.
    Fauci AS
    Emerg Infect Dis; 2006 Jan; 12(1):73-7. PubMed ID: 16494721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.